Mangoceuticals (MGRX) Retained Earnings (2022 - 2026)

Mangoceuticals has disclosed Retained Earnings across 5 years of filings, most recently posting -$44.1 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$44.1 million, down 1983269.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.1 million (down 1983269.2% YoY), and the FY2025 annual result was -$2760.0, up 71.97% from the prior year.
• Retained Earnings came in at -$44.1 million for Q1 2026 at Mangoceuticals, down from -$2760.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$1166.0 in Q2 2024 to a low of -$44.1 million in Q1 2026.
• The 5-year median for Retained Earnings is -$3.3 million (2022), against an average of -$7.8 million.
• Across the five-year window, Retained Earnings surged 99.99% in 2025 and plunged 1983269.2% in 2026, its largest moves.
• Mangoceuticals' Retained Earnings stood at -$2.0 million in 2022, then sank by 457.02% to -$11.2 million in 2023, then surged by 99.91% to -$9845.0 in 2024, then surged by 71.97% to -$2760.0 in 2025, then sank by 1595937.32% to -$44.1 million in 2026.
• The last three Retained Earnings figures came in at -$44.1 million (Q1 2026), -$2760.0 (Q4 2025), and -$2079.0 (Q3 2025), per Business Quant data.